John Strasswimmer, MD
Dermatology · Delray Beach, FLNPI 1871577700
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $392,896 of the $560,322 with a category attached, or 70.1%. Regeneron Healthcare Solutions, Inc. accounts for 62.9% of it on its own, with 33 other manufacturers making up the rest. 2025 is the largest year on record at $157,817, 8.0 times the $19,738 reported in 2019. Among dermatology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 474 payments — averaging $1182.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$353K
- Regeneron$66K
- Genentech USA, Inc.$46K
- Sanofi$38K
- Kerecis Limited$32K
- Sun Pharmaceutical Industries Inc.$17K
- plus $9K from 28 others
Across 201 payments — averaging $4327.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$723K
- Biofrontera Bioscience GmbH$96K
- Biofrontera Inc.$42K
- AbbVie$10K
What the payments were for
- Consulting fees$109,43620%
- Speaking & faculty fees$392,89670%
- Travel & lodging$38,7977%
- Food & beverage$12,0632%
- Education$7,1191%
- Gifts$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 214 | $352,686 |
| Regeneron | 25 | $66,088 |
| Genentech USA, Inc. | 37 | $46,330 |
| Sanofi | 32 | $38,241 |
| Kerecis Limited | 52 | $31,570 |
| Sun Pharmaceutical Industries Inc. | 33 | $16,830 |
| Biofrontera Inc. | 13 | $4,387 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 1 | $1,000 |
| LEO Pharma AS | 1 | $600 |
| Biofrontera Bioscience GmbH | 3 | $524 |
| AbbVie(2 entities) | 6 | $344 |
| Prugen, Inc. Pharmaceuticals | 2 | $279 |
| Incyte Corporation | 3 | $175 |
| Lilly USA, LLC | 8 | $170 |
| Galderma Laboratories, L.p. | 2 | $156 |
| Helsinn Therapeutics (U.S.), Inc. | 7 | $123 |
| Paratek Pharmaceuticals, Inc. | 4 | $99 |
| Amgen | 4 | $97 |
| Almirall LLC | 2 | $90 |
| Merz North America, Inc. | 3 | $75 |
| Pfizer | 4 | $58 |
| Polynovo North America LLC | 1 | $48 |
| Organogenesis Inc. | 2 | $47 |
| Johnson & Johnson | 2 | $46 |
| Merck | 2 | $40 |
| Novartis | 2 | $38 |
| AstraZeneca | 1 | $32 |
| Misonix Inc | 2 | $32 |
| VYNE Pharmaceuticals Inc. | 1 | $22 |
| Nabriva Therapeutics, PLC | 1 | $22 |
| DUSA Pharmaceuticals, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| Journey Medical Corporation | 1 | $18 |
| Solventum Corporation | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$459,784
- Kerecis SurgiClose$119,818
- Erivedge$45,884
- Kerecis GraftGuide$29,954
- Unloxcyt$10,383
- ODOMZO$5,539
- AMELUZ$4,746
- BF-RhodoLED$4,233
- Kerecis Omega3 Marigen$3,522
- XEPI$3,108
- Surgical wound closure product$1,000
- Kerecis Omega3 SurgiClose$947
- BF-RhodoLED XL$513
- Kerecis Omega3 GraftGuide$266
- NEMLUVIO$137
- DUPIXENT$133
- Rinvoq$125
- OPZELURA$125
- BOTOX COSMETIC$120
How this compares
$560,322 in reported general payments places this provider in the 95th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 421 | $2,561 |
| Ketoconazole | 70 | $1,093 |
| Fluorouracil | 15 | $897 |
| Triamcinolone Acetonide | 70 | $687 |
| Clindamycin Phosphate | 19 | $647 |
| Gentamicin Sulfate | 16 | $589 |
| Doxycycline Monohydrate | 35 | $513 |
| Mupirocin | 81 | $458 |
| Ammonium Lactate | 19 | $443 |
| Hydrocortisone | 49 | $217 |
| Cephalexin | 19 | $198 |
| Amoxicillin | 31 | $32 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Delray Beach
- Janet AllenbyDelray Beach$459K
- Francesca LewisDelray Beach$175K
- Francisco KerdelMiami$2.1M
- Brad GlickMargate$2M
- Robert KirsnerMiami$1.4M
- John MinniStuart$1.4M
- Gil YosipovitchMiami$1M
- Shino Bay AguileraFt Lauderdale$1M
- Robert SnyderPembroke Pines$1M
- Marc IngleseTallahassee$989K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.